AbCellera to Release Phase 2 Menopause Drug Data Monday; Shares Jump 8%
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera will release top-line Phase 2 data for ABCL635, its non-hormonal menopause symptom drug, before market open Monday. The stock surged 8% in after-hours trading to $7.48, reflecting anticipation of a potential catalyst. This follows a series of positive developments, including major collaborations with Jazz and Vertex and a strengthened cash position. The data readout could validate the company's internal pipeline and drive further upside if results are strong.
At the time of this announcement, ABCL was trading at $7.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.75 to $8.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.